Vitamin D signaling and melanoma: Role of Vitamin D and its receptors in melanoma progression and management

Andrzej T. Slominski, Anna A. Brozyna, Michal A. Zmijewski, Wojciech Józwicki, Anton M. Jetten, Rebecca S. Mason, Robert C. Tuckey, Craig A. Elmets

Research output: Contribution to journalReview article

33 Citations (Scopus)

Abstract

Ultraviolet B (UVB), in addition to having carcinogenic activity, is required for the production of vitamin D3 (D3) in the skin which supplies >90% of the body's requirement. Vitamin D is activated through hydroxylation by 25-hydroxylases (CYP2R1 or CYP27A1) and 1α-hydroxylase (CYP27B1) to produce 1,25(OH) 2 D3, or through the action of CYP11A1 to produce mono-di-and trihydroxy-D3 products that can be further modified by CYP27B1, CYP27A1, and CYP24A1. The active forms of D3, in addition to regulating calcium metabolism, exert pleiotropic activities, which include anticarcinogenic and anti-melanoma effects in experimental models, with photoprotection against UVB-induced damage. These diverse effects are mediated through an interaction with the vitamin D receptor (VDR) and/or as most recently demonstrated through action on retinoic acid orphan receptors (ROR)α and RORÎ 3. With respect to melanoma, low levels of 25(OH)D are associated with thicker tumors and reduced patient survival. Furthermore, single-nucleotide polymorphisms of VDR and the vitamin D-binding protein (VDP) genes affect melanomagenesis or disease outcome. Clinicopathological analyses have shown positive correlation between low or undetectable expression of VDR and/or CYP27B1 in melanoma with tumor progression and shorter overall (OS) and disease-free survival (DFS) times. Paradoxically, this correlation was reversed for CYP24A1 (inactivating 24-hydroxylase), indicating that this enzyme, while inactivating 1,25(OH) 2 D3, can activate other forms of D3 that are products of the non-canonical pathway initiated by CYP11A1. An inverse correlation has been found between the levels of RORα and RORÎ 3 expression and melanoma progression and disease outcome. Therefore, we propose that defects in vitamin D signaling including D3 activation/inactivation, and the expression and activity of the corresponding receptors, affect melanoma progression and the outcome of the disease. The existence of multiple bioactive forms of D3 and alternative receptors affecting the behavior of melanoma should be taken into consideration when applying vitamin D management for melanoma therapy.

Original languageEnglish
Pages (from-to)706-724
Number of pages19
JournalLaboratory Investigation
Volume97
Issue number6
DOIs
Publication statusPublished - 1 Jun 2017

Fingerprint

Calcitriol Receptors
Vitamin D
Melanoma
25-Hydroxyvitamin D3 1-alpha-Hydroxylase
Mixed Function Oxygenases
Cholesterol Side-Chain Cleavage Enzyme
Disease Progression
Vitamin D-Binding Protein
Retinoic Acid Receptors
Cholecalciferol
Hydroxylation
Disease-Free Survival
Single Nucleotide Polymorphism
Neoplasms
Theoretical Models
Calcium
Skin
Survival
Enzymes
Genes

Cite this

Slominski, A. T., Brozyna, A. A., Zmijewski, M. A., Józwicki, W., Jetten, A. M., Mason, R. S., ... Elmets, C. A. (2017). Vitamin D signaling and melanoma: Role of Vitamin D and its receptors in melanoma progression and management. Laboratory Investigation, 97(6), 706-724. https://doi.org/10.1038/labinvest.2017.3
Slominski, Andrzej T. ; Brozyna, Anna A. ; Zmijewski, Michal A. ; Józwicki, Wojciech ; Jetten, Anton M. ; Mason, Rebecca S. ; Tuckey, Robert C. ; Elmets, Craig A. / Vitamin D signaling and melanoma : Role of Vitamin D and its receptors in melanoma progression and management. In: Laboratory Investigation. 2017 ; Vol. 97, No. 6. pp. 706-724.
@article{456c3e081c6147d98ccbc76a163fdca2,
title = "Vitamin D signaling and melanoma: Role of Vitamin D and its receptors in melanoma progression and management",
abstract = "Ultraviolet B (UVB), in addition to having carcinogenic activity, is required for the production of vitamin D3 (D3) in the skin which supplies >90{\%} of the body's requirement. Vitamin D is activated through hydroxylation by 25-hydroxylases (CYP2R1 or CYP27A1) and 1α-hydroxylase (CYP27B1) to produce 1,25(OH) 2 D3, or through the action of CYP11A1 to produce mono-di-and trihydroxy-D3 products that can be further modified by CYP27B1, CYP27A1, and CYP24A1. The active forms of D3, in addition to regulating calcium metabolism, exert pleiotropic activities, which include anticarcinogenic and anti-melanoma effects in experimental models, with photoprotection against UVB-induced damage. These diverse effects are mediated through an interaction with the vitamin D receptor (VDR) and/or as most recently demonstrated through action on retinoic acid orphan receptors (ROR)α and ROR{\^I} 3. With respect to melanoma, low levels of 25(OH)D are associated with thicker tumors and reduced patient survival. Furthermore, single-nucleotide polymorphisms of VDR and the vitamin D-binding protein (VDP) genes affect melanomagenesis or disease outcome. Clinicopathological analyses have shown positive correlation between low or undetectable expression of VDR and/or CYP27B1 in melanoma with tumor progression and shorter overall (OS) and disease-free survival (DFS) times. Paradoxically, this correlation was reversed for CYP24A1 (inactivating 24-hydroxylase), indicating that this enzyme, while inactivating 1,25(OH) 2 D3, can activate other forms of D3 that are products of the non-canonical pathway initiated by CYP11A1. An inverse correlation has been found between the levels of RORα and ROR{\^I} 3 expression and melanoma progression and disease outcome. Therefore, we propose that defects in vitamin D signaling including D3 activation/inactivation, and the expression and activity of the corresponding receptors, affect melanoma progression and the outcome of the disease. The existence of multiple bioactive forms of D3 and alternative receptors affecting the behavior of melanoma should be taken into consideration when applying vitamin D management for melanoma therapy.",
author = "Slominski, {Andrzej T.} and Brozyna, {Anna A.} and Zmijewski, {Michal A.} and Wojciech J{\'o}zwicki and Jetten, {Anton M.} and Mason, {Rebecca S.} and Tuckey, {Robert C.} and Elmets, {Craig A.}",
year = "2017",
month = "6",
day = "1",
doi = "10.1038/labinvest.2017.3",
language = "English",
volume = "97",
pages = "706--724",
journal = "Laboratory Investigation",
issn = "0023-6837",
publisher = "Nature Publishing Group",
number = "6",

}

Slominski, AT, Brozyna, AA, Zmijewski, MA, Józwicki, W, Jetten, AM, Mason, RS, Tuckey, RC & Elmets, CA 2017, 'Vitamin D signaling and melanoma: Role of Vitamin D and its receptors in melanoma progression and management' Laboratory Investigation, vol. 97, no. 6, pp. 706-724. https://doi.org/10.1038/labinvest.2017.3

Vitamin D signaling and melanoma : Role of Vitamin D and its receptors in melanoma progression and management. / Slominski, Andrzej T.; Brozyna, Anna A.; Zmijewski, Michal A.; Józwicki, Wojciech; Jetten, Anton M.; Mason, Rebecca S.; Tuckey, Robert C.; Elmets, Craig A.

In: Laboratory Investigation, Vol. 97, No. 6, 01.06.2017, p. 706-724.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Vitamin D signaling and melanoma

T2 - Role of Vitamin D and its receptors in melanoma progression and management

AU - Slominski, Andrzej T.

AU - Brozyna, Anna A.

AU - Zmijewski, Michal A.

AU - Józwicki, Wojciech

AU - Jetten, Anton M.

AU - Mason, Rebecca S.

AU - Tuckey, Robert C.

AU - Elmets, Craig A.

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Ultraviolet B (UVB), in addition to having carcinogenic activity, is required for the production of vitamin D3 (D3) in the skin which supplies >90% of the body's requirement. Vitamin D is activated through hydroxylation by 25-hydroxylases (CYP2R1 or CYP27A1) and 1α-hydroxylase (CYP27B1) to produce 1,25(OH) 2 D3, or through the action of CYP11A1 to produce mono-di-and trihydroxy-D3 products that can be further modified by CYP27B1, CYP27A1, and CYP24A1. The active forms of D3, in addition to regulating calcium metabolism, exert pleiotropic activities, which include anticarcinogenic and anti-melanoma effects in experimental models, with photoprotection against UVB-induced damage. These diverse effects are mediated through an interaction with the vitamin D receptor (VDR) and/or as most recently demonstrated through action on retinoic acid orphan receptors (ROR)α and RORÎ 3. With respect to melanoma, low levels of 25(OH)D are associated with thicker tumors and reduced patient survival. Furthermore, single-nucleotide polymorphisms of VDR and the vitamin D-binding protein (VDP) genes affect melanomagenesis or disease outcome. Clinicopathological analyses have shown positive correlation between low or undetectable expression of VDR and/or CYP27B1 in melanoma with tumor progression and shorter overall (OS) and disease-free survival (DFS) times. Paradoxically, this correlation was reversed for CYP24A1 (inactivating 24-hydroxylase), indicating that this enzyme, while inactivating 1,25(OH) 2 D3, can activate other forms of D3 that are products of the non-canonical pathway initiated by CYP11A1. An inverse correlation has been found between the levels of RORα and RORÎ 3 expression and melanoma progression and disease outcome. Therefore, we propose that defects in vitamin D signaling including D3 activation/inactivation, and the expression and activity of the corresponding receptors, affect melanoma progression and the outcome of the disease. The existence of multiple bioactive forms of D3 and alternative receptors affecting the behavior of melanoma should be taken into consideration when applying vitamin D management for melanoma therapy.

AB - Ultraviolet B (UVB), in addition to having carcinogenic activity, is required for the production of vitamin D3 (D3) in the skin which supplies >90% of the body's requirement. Vitamin D is activated through hydroxylation by 25-hydroxylases (CYP2R1 or CYP27A1) and 1α-hydroxylase (CYP27B1) to produce 1,25(OH) 2 D3, or through the action of CYP11A1 to produce mono-di-and trihydroxy-D3 products that can be further modified by CYP27B1, CYP27A1, and CYP24A1. The active forms of D3, in addition to regulating calcium metabolism, exert pleiotropic activities, which include anticarcinogenic and anti-melanoma effects in experimental models, with photoprotection against UVB-induced damage. These diverse effects are mediated through an interaction with the vitamin D receptor (VDR) and/or as most recently demonstrated through action on retinoic acid orphan receptors (ROR)α and RORÎ 3. With respect to melanoma, low levels of 25(OH)D are associated with thicker tumors and reduced patient survival. Furthermore, single-nucleotide polymorphisms of VDR and the vitamin D-binding protein (VDP) genes affect melanomagenesis or disease outcome. Clinicopathological analyses have shown positive correlation between low or undetectable expression of VDR and/or CYP27B1 in melanoma with tumor progression and shorter overall (OS) and disease-free survival (DFS) times. Paradoxically, this correlation was reversed for CYP24A1 (inactivating 24-hydroxylase), indicating that this enzyme, while inactivating 1,25(OH) 2 D3, can activate other forms of D3 that are products of the non-canonical pathway initiated by CYP11A1. An inverse correlation has been found between the levels of RORα and RORÎ 3 expression and melanoma progression and disease outcome. Therefore, we propose that defects in vitamin D signaling including D3 activation/inactivation, and the expression and activity of the corresponding receptors, affect melanoma progression and the outcome of the disease. The existence of multiple bioactive forms of D3 and alternative receptors affecting the behavior of melanoma should be taken into consideration when applying vitamin D management for melanoma therapy.

UR - http://www.scopus.com/inward/record.url?scp=85019724568&partnerID=8YFLogxK

U2 - 10.1038/labinvest.2017.3

DO - 10.1038/labinvest.2017.3

M3 - Review article

VL - 97

SP - 706

EP - 724

JO - Laboratory Investigation

JF - Laboratory Investigation

SN - 0023-6837

IS - 6

ER -